ADA
ADA (adenosine deaminase, also known as ADA1) is a metallo-dependent hydrolase that catalyses the hydrolytic deamination of adenosine and 2-deoxyadenosine. It has a central role in purine metabolism and adenosine homeostasis, and it contributes to immune function. Browse Assay Genie's current range of ADA research reagents below, or read on for the biology behind the target.
ADA catalyses the hydrolysis of adenosine to inosine in the purine catabolic pathway, and also acts on 2-deoxyadenosine. By controlling adenosine levels it modulates signalling by extracellular adenosine and so contributes indirectly to cellular signalling events. The enzyme also deaminates cordycepin (3'-deoxyadenosine), a fungal natural product with antitumour, antibacterial, antifungal, antiviral and immune-regulating properties.
Beyond its catalytic role, ADA takes part in immune regulation. It acts as a positive regulator of T-cell coactivation by binding DPP4, and this interaction regulates lymphocyte-epithelial cell adhesion. ADA enhances dendritic cell immunogenicity by affecting costimulatory molecule expression and cytokine and chemokine secretion, and it enhances CD4+ T-cell differentiation and proliferation. It is also a positive modulator of the adenosine receptors ADORA1 and ADORA2A, increasing their ligand affinity through a conformational change. Other annotated roles include stimulation of plasminogen activation, a role in male fertility and a protective role in early postimplantation embryonic development.
The ADA gene belongs to the adenosine deaminase gene group, and the protein is a member of the metallo-dependent hydrolases superfamily and the adenosine and AMP deaminases family. UniProt records localisation to the cell membrane, cell junction, cytoplasm, cytoplasmic vesicle lumen and lysosome. Mutations in the gene are linked to impaired immune function, notably severe combined immunodeficiency disease (SCID), in which ADA deficiency leads to marked depletion of T, B and NK lymphocytes and a lack of both humoral and cellular immunity. Conversely, elevated enzyme levels are associated with congenital haemolytic anaemia.
ADA converts adenosine to inosine in the purine catabolic pathway, making it a core enzyme for studying nucleoside turnover and adenosine homeostasis.
ADA deficiency causes SCID with depletion of T, B and NK lymphocytes, so the enzyme is central to studies of immune development.
ADA binds DPP4 to promote T-cell coactivation and enhances dendritic cell immunogenicity and CD4+ T-cell proliferation.
ADA enhances ligand affinity of ADORA1 and ADORA2A and modulates extracellular adenosine signalling, relevant to purinergic pathway research.
ADA catalyses the hydrolytic deamination of adenosine and 2-deoxyadenosine, playing an important role in purine metabolism and adenosine homeostasis. It also binds DPP4 to support T-cell coactivation and enhances the ligand affinity of adenosine receptors ADORA1 and ADORA2A.
The HGNC-approved name is adenosine deaminase, and the gene symbol ADA has the alias ADA1. It is classed in the adenosine deaminase gene group and carries the enzyme classification EC 3.5.4.4. It should not be confused with the related gene ADA2.
Yes. ADA mutations cause severe combined immunodeficiency disease, while elevated enzyme levels are associated with congenital haemolytic anaemia. Mouse and rat each have an orthologous Ada gene; check the datasheet of any product for its validated reactivity.
Other adenosine deaminase family members and similarly named ADAM and ADAMTS proteins with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P00813; product specifications from Assay Genie datasheets.